Medera to go public via SPAC merger with KVAC in a $623m deal.

Medera, a clinical-stage biopharmaceutical company, to go public via SPAC merger with Keen Vision Acquisition, a blank check company, in a $623m deal. "Achieving a Nasdaq listing will allow Medera to be better positioned for advancing our various clinical and preclinical programs, enabling more efficient development aimed at bringing novel therapeutic solutions to patients with unmet needs," Ronald Li, PhD, Medera Founder and CEO.